Search clinical trials for: NMIBC

Total 128 results

RemeGen Co., Ltd.

Not yet recruiting

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

High-risk Non-muscle Invasive Bladder Cancer

China
Ractigen Therapeutics.

Recruiting

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Australia
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
Huashan Hospital

Not yet recruiting

Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC

Bladder Cancer
European Organisation for Research and Treatment...

Not yet recruiting

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

Bladder Cancer
The First Affiliated Hospital with Nanjing Medical...

Recruiting

The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection

Non Muscle Invasive Bladder Cancer

China
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

Non-muscle Invasive Bladder Cancer

United States
Istituto Oncologico Veneto IRCCS
Fidia Farmaceutici s.p.a.

Not yet recruiting

A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer (Hydeal Cyst)

Non-muscle Invasive Bladder Cancer

Italy
Chengdu CoenBiotech Co., Ltd
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Non-Muscle Invasive Bladder Cancer

China
University of Bern
Spitalzentrum Biel

Not yet recruiting

Precise Neoadjuvant Chemoresection of Low Grade NMIBC (POLO)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Low-risk

Switzerland
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)

Non-Muscle Invasive Bladder Neoplasms

Korea, Republic of, United States, United Kingdom
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC

Non-Muscle-Invasive Bladder Cancer (NMIBC)

China
Prokarium Ltd

Recruiting

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer (PARADIGM-1)

NMIBC | Non Muscle Invasive Bladder Cancer | High Risk NMIBC

United States
Mayo Clinic

Recruiting

Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)

Non-muscle Invasive Bladder Cancer | Stage 0a Bladder Cancer AJCC v8 | NMIBC

United States
CG Oncology, Inc.

Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder Cancer

United States
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

High-risk Non-muscle Invasive Bladder Cancer

China
Ferring Pharmaceuticals

Recruiting

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States (ABLE-41)

Bladder Cancer

United States
Qilu Hospital of Shandong University

Recruiting

Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Bladder Cancer

China
University of Roma La Sapienza

Not yet recruiting

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) (CUT-less)

Non-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
RenJi Hospital
BeiGene; RemeGen Co., Ltd.

Recruiting

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

HER2 | Non-Muscle Invasive Bladder Cancer

China
Protara Therapeutics

Recruiting

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-2)

Non-muscle Invasive Bladder Cancer

United States, Ukraine
AstraZeneca
Parexel

Recruiting

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (PATAPSCO)

Non-Muscle- Invasive Bladder Cancer

United States
RemeGen Co., Ltd.

Recruiting

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

NMIBC

China
University of Texas Southwestern Medical Center

Recruiting

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

Non-muscle-invasive Bladder Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense

Recruiting

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

Urothelial Carcinoma | Non-Invasive Bladder Urothelial Carcinoma

United States
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

Bladder Cancer

United States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
Ferring Pharmaceuticals

Recruiting

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer

Japan
University of Arizona

Recruiting

Intravesical Gemcitabine in Patients With NMIBC

Urinary Bladder Cancer

United States
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BL-PDT-RCT)

Non-muscle-invasive Bladder Cancer

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)

Non-muscle-invasive Bladder Cancer

United States
VA Office of Research and Development
University of California, Davis

Recruiting

A Phase I Intravesical PPM Therapy for NMIBC

Non-muscle-invasive Bladder Cancer

United States
Aura Biosciences

Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-1501 Alone or in Combination With BCG in Subjects With NMIBC

High-risk NMIBC

China
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
Vitadx
FONDATION FORCE POUR L'INNOVATION ET LA RECHERCHE EN SANTE

Recruiting

Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test (DMIA)

Non-muscle Invasive Bladder Cancer (NMIBC)

France, Belgium, Spain
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Relationship Between Lymph Node Dissection and Prognosis in High-risk NMIBC

Bladder Cancer

China
Protara Therapeutics

Recruiting

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (ADVANCED-1)

Non-muscle Invasive Bladder Cancer

United States, Moldova, Republic of, Romania, Ukraine
Protara Therapeutics

Recruiting

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-1)

Non-muscle Invasive Bladder Cancer

United States
Verity Pharmaceuticals Inc.

Not yet recruiting

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (EVER)

Bladder Cancer | Urothelial Carcinoma Bladder | Bladder Cancer Recurrent | Neoplasm Recurrence | Urothelial Carcinoma Recurrent | Non-Invasive Bladder Urothelial Carcinoma
Astellas Pharma Global Development, Inc.
Seagen Inc.

Recruiting

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Carcinoma in Situ | Urinary Bladder Neoplasms | Non-muscle Invasive Bladder Cancer | Carcinoma Transitional Cell | NMIBC

United States, Canada, France, Spain, United Kingdom, Germany
RenJi Hospital
BeiGene; Huidu Shanghai Medical Sciences Ltd

Recruiting

Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) (TACBIN-01)

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Antineoplastic Agents | Tislelizumab Antineoplastic Agents, Immunological

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Bladder Cancer | Recurrent Bladder Cancer | FGFR3 Gene Mutation

United States
Benha University

Recruiting

Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT

Bladder Cancer | Bladder Neoplasm

Egypt
Lindis Biotech GmbH

Recruiting

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Urinary Bladder Neoplasms

Germany
University Teaching Hospital Hall in Tirol
Salzburger Landeskliniken

Recruiting

CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood

Neoplasms | Urogenital Neoplasms | Transitional Cell Carcinoma | Circulating Tumor Cell | Urinary Bladder Neoplasm

Austria
enGene, Inc.

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Superficial Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

United States
Taizhou Hanzhong biomedical co. LTD

Recruiting

Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Cancer

China
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients (ASCERTAIN)

Non-muscle Invasive Bladder Cancer

China
Fudan University
Shanghai Shen Kang Hospital Development Center

Recruiting

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Urinary Bladder Neoplasms | Immunotherapy

China
Mansoura University

Recruiting

Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Cancer

Egypt

Search clinical trials for: NMIBC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations